United Kingdom Excipients Market

Market Snapshot

• Market Size (2025): USD 891.2 Million
• Projected Market Size (2035): USD 1642.3 Million
• Compound Annual Growth Rate (CAGR): 6.3%
• Base Year: 2025
• Historical Period: 2021–2025
• Forecast Period: 2026–2035

According to Decision Advisors, the United Kingdom Excipients Market Size is expected to grow from USD 891.2million in 2025 to USD 1642.3million by 2035, at a CAGR of 6.3% during the forecast period 2025-2035. The United Kingdom excipients market is projected to grow significantly over the next decade due to an aging population, increased R&D for multifunctional excipients, and regulatory focus on safety, complex drug formulations, and the rise of generic medicines.

 

Market Overview/Introduction

The UK excipients market consists of three main activities, which include manufacturing, distributing, and selling inactive substances that pharmaceutical companies, nutraceutical manufacturers, and biopharmaceutical developers use to create stable drug formulations. The performance of active pharmaceutical ingredients improves through the use of excipients, which include binders and fillers, and lubricants and stabilizers that do not provide any medicinal benefits. Right now, the UK is moving past basic filler ingredients and stepping into an era of high-tech, functional materials. The process now requires more than simply packing a capsule because it needs to create medicines that provide better results for patients who use them. The UK government Life Sciences Fund provides its major support to this transformation, which aims to establish the country as a self-sufficient leader in pharmaceutical manufacturing. At the same time, British giants like Croda are ditching old-school methods for high-tech, plant-based materials that are much kinder to the planet. The real game-changer, though, is personalized medicine where smart ingredients are custom-tailored to a patient’s own biology, ensuring the treatment hits exactly when and where it's needed. As the UK continues to lead in genomics and 3D-printed drugs, seeing a massive opportunity for smart ingredients. These are custom-tailored to a patient’s own biology, ensuring that complex therapies are not only more effective but also released exactly when and where the body needs them most.

 

• Croda Pharma’s Super Refined excipients supported drug formulators by delivering consistent purity and performance across various excipient chemistries. This development strengthened the UK excipients market by enhancing formulation reliability, improving drug quality standards, and supporting advanced pharmaceutical manufacturing capabilities.

 

• The UK introduced a strategic framework to add $41 billion to its life sciences sector by 2035. Reforms to MHRA and NICE improved regulatory efficiency and reimbursement pathways, indirectly boosting excipients demand by accelerating pharmaceutical innovation and product approvals.

 

Notable Insights: -

1. The polymers segment dominated the market in 2025 and is projected to grow at a substantial CAGR of approximately 6.6% during the forecast period.
2. The tablets segment accounted for the largest share in 2025 and is anticipated to grow at a significant CAGR of approximately 12 % during the forecast period.
3. The oral dosage forms segment dominated the market in 2025 and is projected to grow at a substantial CAGR of approximately 6.5% during the forecast period.
4. The compound annual growth rate of the United Kingdom excipients market is 6.3%.
5. The market is likely to achieve a valuation of USD 1642.3million by 2035.

 

What is the role of technology in grooming the market?

Technology plays a transformative role in shaping the United Kingdom excipients market by enabling the development of advanced, multifunctional excipients that improve drug stability, solubility, and targeted delivery. Innovations such as nanotechnology, 3D printing, and continuous manufacturing enhance formulation efficiency and reduce production costs. Digital tools and AI-driven analytics support faster drug development and quality control. Additionally, technology facilitates compliance with evolving regulatory standards and supports personalized medicine trends. These advancements are driving demand for high-performance excipients, positioning the UK as a key hub for innovation and growth in the global pharmaceutical excipients market.

 

Market Drivers

The United Kingdom excipients market is driven by rising demand for advanced formulation solutions that improve drug stability, bioavailability, and patient compliance. Increasing focus on biologics, biosimilars, and precision medicines has accelerated the need for high-quality and functional excipients. The growth of contract manufacturing organizations and the expansion of pharmaceutical production facilities further support market expansion. Additionally, continuous innovation in drug delivery technologies, including sustained and targeted release systems, is boosting excipient utilization. Strong regulatory emphasis on quality standards and traceability, along with increasing investments in research collaborations between academia and industry, are further propelling the adoption of specialized excipients across the UK pharmaceutical sector.

 

Restrain

The United Kingdom excipients market faces restraints due to stringent regulatory requirements, high development and compliance costs, and supply chain disruptions post-Brexit. Limited availability of novel excipients and lengthy approval timelines also hinder innovation, while price pressures from generic drug manufacturers restrict overall market profitability and growth potential.

 

Strategies to Implement for Growth of the Market

• Invest in R&D to develop multifunctional and high-performance excipients for advanced drug formulations
• Strengthen local manufacturing capabilities to reduce dependency on imports post-Brexit
• Focus on regulatory compliance and faster approval pathways for novel excipients
• Adopt advanced technologies such as AI, continuous manufacturing, and nanotechnology
• Collaborate with pharmaceutical companies for co-development and innovation
• Expand into biopharmaceutical excipients to support growing biologics demand
• Enhance supply chain resilience through diversified sourcing and digital tracking
• Target patient-centric formulations like controlled-release and pediatric-friendly dosage forms
• Leverage partnerships and mergers to expand product portfolios and market reach
• Increase focus on sustainability with eco-friendly and biodegradable excipient solutions.

 

Market Segmentation

The United Kingdom excipients market share is classified into product type, distribution channel, and alcohol volume  

 

• The polymers segment dominated the market in 2025 and is projected to grow at a substantial CAGR of approximately 6.6% during the forecast period.

Based on the product type, the excipients market is divided into polymers, alcohols, sugars, minerals, and gelatin. Among these, the polymers segment dominated the market in 2025 and is projected to grow at a substantial CAGR of approximately 6.6% during the forecast period. The polymers segment is driven by rising demand for advanced drug delivery systems in the UK, where polymers enhance stability, solubility, and controlled release. Growth in biologics, generics, and personalized medicines, along with strong pharmaceutical R&D and regulatory support, further accelerates the adoption of functional and multifunctional polymer excipients.

 

• The tablets segment accounted for the largest share in 2025 and is anticipated to grow at a significant CAGR of approximately 12 % during the forecast period.

Based on the formulation, the excipients market is divided into tablets, capsules, parenteral, topical, and liquid dosage forms. Among these, the tablets segment accounted for the largest share in 2025 and is anticipated to grow at a significant CAGR of approximately 12 % during the forecast period. The tablets segment in the U.S. is driven by high demand for oral solid dosage forms due to their convenience, cost-efficiency, and patient compliance. Strong presence of generic drug manufacturers, increasing chronic disease prevalence, and advanced manufacturing technologies further boost large-scale tablet production, supporting significant market growth.

 

• The oral dosage forms segment dominated the market in 2025 and is projected to grow at a substantial CAGR of approximately 6.5% during the forecast period.

Based on the application, the excipients market is divided into oral dosage forms, injectable formulations, topical applications, inhalation products, ophthalmic preparations, and nutraceuticals & R&D. Among these, the oral dosage forms segment dominated the market in 2025, and is projected to grow at a substantial CAGR of approximately 6.5% during the forecast period. The oral dosage forms segment in the U.S. is driven by strong demand for convenient and non-invasive drug delivery systems, particularly for chronic disease management. High consumption of generics and OTC drugs, well-established pharmaceutical manufacturing infrastructure, and continuous innovation in oral formulations further support sustained market growth.

 

Recent Development

In June 2025, Indoco Remedies announced the launch of Ticagrelor film-coated tablets in the UK through its subsidiary. The development supported the demand, as increased tablet production and cardiovascular drug availability contributed to growth in pharmaceutical manufacturing and formulation activities.

 

In September 2024, Merck achieved EXCiPACT cGMP certification for pharmaceutical auxiliary materials across its global production sites. This milestone strengthened quality assurance in excipient manufacturing, supported regulatory compliance, and positively influenced the UK market by ensuring high standards and reliable excipient supply.

 

Competitive Analysis

The report offers the appropriate analysis of the key organisations/companies involved within the United Kingdom excipients market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

Top Key Companies in United Kingdom Excipients market

• BASF SE
• Roquette Frères
• Ashland Inc.
• Croda International Plc
• Evonik Industries AG
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Market Segment

This study forecasts revenue at the United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom excipients market based on the below-mentioned segments

 

United Kingdom United Kingdom Excipients market, By Product Type

• Polymers
• Alcohols
• Sugars
• Minerals
• Gelatin

 

United Kingdom United Kingdom Excipients market, By Formulation

• Tablets
• Capsules
• Parenteral
• Topical
• Liquid dosage form

 

United Kingdom United Kingdom Excipients market, By Application

• Oral dosage forms
• Injectable formulations
• Topical applications
• Inhalation products
• Ophthalmic preparations
• Nutraceuticals & R&D

 

Frequently Asked Questions (FAQ)

Q. How is the demand for biopharmaceuticals influencing the UK excipients market?

A. The increasing adoption of biologics and biosimilars in the UK is driving demand for specialized excipients that support stability, solubility, and delivery of complex molecules, thereby boosting innovation and expanding the excipients market.

 

Q. What role do contract manufacturing organizations (CMOs) play in the UK excipients market?

A. CMOs significantly contribute by increasing large-scale drug production, which elevates the need for consistent, high-quality excipients and supports overall market growth through outsourcing trends in pharmaceutical manufacturing.

 

Q. How does sustainability impact excipient development in the UK?

A. Sustainability initiatives are encouraging the development of eco-friendly and biodegradable excipients, as companies aim to reduce environmental impact and comply with evolving regulatory and consumer expectations.

 

Q. Why is quality assurance critical in the UK excipients market?

A. Strict regulatory frameworks in the UK require high standards of purity, safety, and traceability, making quality assurance essential for ensuring compliance, maintaining product consistency, and supporting pharmaceutical innovation.